 |
6 Products |  |
6 Diseases | | 6 Products |
|
997 Trials |  |
3075 News |  |
| 12345678910111213...5152» |
- | Oncorine (recombinant human adenovirus type 5) / Mergen Ltd., AiRuiKa (camrelizumab) / HLB Bio Group
Journal, PD(L)-1 Biomarker, IO biomarker: Oncolytic adenovirus H101 enhances the anti-tumor effects of PD-1 blockade via CD47 downregulation in tumor cells. (Pubmed Central) - Apr 29, 2025
To investigate the anti-tumor effects of an E1B55KD-deleted oncolytic adenovirus, H101, in combination with a humanized anti-PD-1 (Programmed cell death protein 1) monoclonal antibody, Camrelizumab...These results suggested that H101 may act synergistically to enhance the therapeutic efficacy of PD-1 blockade in cancer via suppressing CD47 signaling, which may promote macrophages to phagocytose tumor cells and activate CD8+ T cells. The combination of H101 with PD-1 blockade exhibits potential as a novel strategy for the treatment of cancer.
- | Tyvyt (sintilimab) / Innovent Biologics, Eli Lilly, Sulanda (surufatinib) / Hutchmed, AiRuiKa (camrelizumab) / HLB Bio Group
Journal, PD(L)-1 Biomarker, IO biomarker: Combining anti-PD-1 antibodies with surufatinib for gastrointestinal neuroendocrine carcinoma: Two cases report and review of literature. (Pubmed Central) - Apr 28, 2025
The combination of H101 with PD-1 blockade exhibits potential as a novel strategy for the treatment of cancer. The combination of antiangiogenic targeted drugs and immunotherapy provides a new therapeutic approach for the treatment of metastatic GI-NECs.
- | Journal, MSi-H Biomarker, PD(L)-1 Biomarker, IO biomarker, dMMR: Case Report: A long-term response of immunotherapy combined with anti-angiogenesis therapy in a patient with dMMR metastatic colorectal cancer after ICI failure. (Pubmed Central) - Apr 27, 2025
After treatment, the patient achieved a complete response, and the disease was sustainably controlled with a progression-free survival (PFS) of 3 years and counting. This report demonstrates that the combination of ICI and anti-angiogenesis therapy can induce a powerful and durable antitumor response in patients with ICI-resistant MSI-H/dMMR mCRC, which is worthy of further research.
- | AiRuiKa (camrelizumab) / HLB Bio Group
Trial completion date, Trial primary completion date: Camrelizumab Combined With AVD in the First-line Treatment for Patients With Advanced Classical Hodgkin's Lymphoma (clinicaltrials.gov) - Apr 25, 2025
P2, N=60, Recruiting, Sponsor: Henan Cancer Hospital
This report demonstrates that the combination of ICI and anti-angiogenesis therapy can induce a powerful and durable antitumor response in patients with ICI-resistant MSI-H/dMMR mCRC, which is worthy of further research. Trial completion date: Dec 2024 --> Dec 2026 | Trial primary completion date: Jun 2024 --> Dec 2025
- AiRuiKa (camrelizumab) / HLB Bio Group
First-line camrelizumab plus chemotherapy in patients with advanced non-squamous non-small cell lung cancer: A nationwide, retrospective real-world study. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_6559;
Trial completion date: Dec 2024 --> Dec 2026 | Trial primary completion date: Jun 2024 --> Dec 2025 The abstract will be released to the public on May 22, 2025 at 5:00 PM EDT
- AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
Camrelizumab plus chemotherapy or apatinib in the first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma: A double-cohort phase II study. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_5920;
P2
The abstract will be released to the public on May 22, 2025 at 5:00 PM EDT Clinical Trial Registration Number: NCT05156970 The abstract will be released to the public on May 22, 2025 at 5:00 PM EDT
- AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
Camrelizumab combined with rivoceranib and TACE in the perioperative treatment of hepatocellular carcinoma: A randomized, open-label multicenter trial. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_5470;
P3
Clinical Trial Registration Number: NCT05156970 The abstract will be released to the public on May 22, 2025 at 5:00 PM EDT Clinical Trial Registration Number: NCT05613478 The abstract will be released to the public on May 22, 2025 at 5:00 PM EDT
- AiRuiKa (camrelizumab) / HLB Bio Group
Real-world analysis of effectiveness in unresectable hepatocellular carcinoma patients treated with camrelizumab-based regimens. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_5469;
Clinical Trial Registration Number: NCT05613478 The abstract will be released to the public on May 22, 2025 at 5:00 PM EDT The abstract will be released to the public on May 22, 2025 at 5:00 PM EDT
- AiRuiKa (camrelizumab) / HLB Bio Group
HIPEC combined with camrelizumab, paclitaxel and S-1 for conversion therapy in patients with advanced gastric cancer with peritoneal metastasis: A prospective phase II clinical study. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_5461;
The abstract will be released to the public on May 22, 2025 at 5:00 PM EDT The abstract will be released to the public on May 22, 2025 at 5:00 PM EDT
- Ibrance (palbociclib) / Pfizer, AiRuiKa (camrelizumab) / HLB Bio Group
A phase I dose-escalation study to evaluate safety and feasibility of neoadjuvant camrelizumab with palbociclib for the treatment of resectable esophageal squamous cell carcinoma (ESCC). () - Apr 23, 2025 - Abstract #ASCO2025ASCO_5369;
P1
The abstract will be released to the public on May 22, 2025 at 5:00 PM EDT Clinical Trial Registration Number: NCT06654297 The abstract will be released to the public on May 22, 2025 at 5:00 PM EDT
- AiRuiKa (camrelizumab) / HLB Bio Group
Camrelizumab combined with concurrent chemoradiotherapy for locally recurrent esophageal cancer: A single-arm, open-label study. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_5356;
P2
Clinical Trial Registration Number: NCT06654297 The abstract will be released to the public on May 22, 2025 at 5:00 PM EDT Clinical Trial Registration Number: NCT04390945 The abstract will be released to the public on May 22, 2025 at 5:00 PM EDT
- AiRuiKa (camrelizumab) / HLB Bio Group
Assessing comparative efficacies of camrelizumab as a single or combination therapy in patients with hepatocellular carcinoma: A systematic review and network meta-analysis. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_5320;
Clinical Trial Registration Number: NCT04390945 The abstract will be released to the public on May 22, 2025 at 5:00 PM EDT The abstract will be released to the public on May 22, 2025 at 5:00 PM EDT
- AiRuiKa (camrelizumab) / HLB Bio Group, Aidixi (disitamab vedotin) / Pfizer
Efficacy and safety of disitamab vedotin (RC48) combined with camrelizumab and S-1 for neoadjuvant therapy of locally advanced gastric cancer with HER2 overexpression: Preliminary results of a prospective, single-arm, phase II study. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_5259;
P2
The abstract will be released to the public on May 22, 2025 at 5:00 PM EDT Clinical Trial Registration Number: ChiCTR2300075446 The abstract will be released to the public on May 22, 2025 at 5:00 PM EDT
- AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
Neoadjuvant systemic chemotherapy combined with camrelizumab (CAM) and apatinib (APA) for BCLC stage A/B hepatocellular carcinoma (HCC) beyond Milan criteria: An interim analysis of a phase 2 trial. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_5256;
Clinical Trial Registration Number: ChiCTR2300075446 The abstract will be released to the public on May 22, 2025 at 5:00 PM EDT Clinical Trial Registration Number: NCT06670107 The abstract will be released to the public on May 22, 2025 at 5:00 PM EDT
- TheraCIM (nimotuzumab) / Daiichi Sankyo, Oncoscience, Biocon, AiRuiKa (camrelizumab) / HLB Bio Group
Camrelizumab plus with nimotuzumab in the second-line treatment of advanced esophageal squamous cell carcinoma: A single-arm, open-label phase II clinical trial. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_5230;
Clinical Trial Registration Number: NCT06670107 The abstract will be released to the public on May 22, 2025 at 5:00 PM EDT The abstract will be released to the public on May 22, 2025 at 5:00 PM EDT
- AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
Perioperative camrelizumab plus apatinib and gemcitabine-oxaliplatin in patients with borderline resectable biliary tract malignancies: A multicenter, single-arm, phase II trial. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_5225;
P2
The abstract will be released to the public on May 22, 2025 at 5:00 PM EDT Clinical Trial Registration Number: NCT05451290 The abstract will be released to the public on May 22, 2025 at 5:00 PM EDT
- Aqupla (nedaplatin) / Simcere, AiRuiKa (camrelizumab) / HLB Bio Group
Camrelizumab combined with paclitaxel and nedaplatin as conversion therapy for locally advanced/advanced esophageal squamous cell carcinoma: A phase II, single-arm exploratory study. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_5224;
P2
Clinical Trial Registration Number: NCT05451290 The abstract will be released to the public on May 22, 2025 at 5:00 PM EDT Clinical Trial Registration Number: ChiCTR2100046355 The abstract will be released to the public on May 22, 2025 at 5:00 PM EDT
- Aqupla (nedaplatin) / Simcere, AiRuiKa (camrelizumab) / HLB Bio Group
Camrelizumab combined with paclitaxel and nedaplatin as neoadjuvant therapy for locally advanced esophageal squamous cell carcinoma (ESPRIT): A phase II, single-arm, exploratory research. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_5223;
P=N/A
Clinical Trial Registration Number: ChiCTR2100046355 The abstract will be released to the public on May 22, 2025 at 5:00 PM EDT Clinical Trial Registration Number: ChiCTR2000033761 The abstract will be released to the public on May 22, 2025 at 5:00 PM EDT
- AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
Cryoablation combined with camrelizumab and apatinib in advanced hepatocellular carcinoma: A prospective, single-arm, phase II study. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_5158;
P2
Clinical Trial Registration Number: ChiCTR2000033761 The abstract will be released to the public on May 22, 2025 at 5:00 PM EDT Clinical Trial Registration Number: NCT04724226 The abstract will be released to the public on May 22, 2025 at 5:00 PM EDT
- AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
Updated results of camrelizumab (Cam) plus low dose apatinib combined with gemcitabine and cisplatin (GP) as first-line therapy for advanced biliary tract cancer (BTC): A single center, phase Ib/II trial. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_5148;
P1/2
Clinical Trial Registration Number: NCT04724226 The abstract will be released to the public on May 22, 2025 at 5:00 PM EDT Clinical Trial Registration Number: NCT05742750 The abstract will be released to the public on May 22, 2025 at 5:00 PM EDT
- Avastin (bevacizumab) / Roche, AiRuiKa (camrelizumab) / HLB Bio Group
Neoadjuvant therapy with mFOLFOXIRI combined with camrelizumab and bevacizumab for microsatellite stable, locally advanced rectal cancer: A single-arm, open-label phase II study. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_5043;
P2
Clinical Trial Registration Number: NCT05742750 The abstract will be released to the public on May 22, 2025 at 5:00 PM EDT Clinical Trial Registration Number: ChiCTR2100054182 The abstract will be released to the public on May 22, 2025 at 5:00 PM EDT
- VG161 / ViroGin Biotech
Oncolytic virus VG161 in combination with camrelizumab as second-line therapy in patients with advanced primary hepatocellular carcinoma: A phase Ib/IIa clinical study. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_4700;
P1/2
Clinical Trial Registration Number: ChiCTR2100054182 The abstract will be released to the public on May 22, 2025 at 5:00 PM EDT Clinical Trial Registration Number: NCT06124001 The abstract will be released to the public on May 22, 2025 at 5:00 PM EDT
- AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
Camrelizumab plus apatinib and chemotherapy as neoadjuvant therapy for triple negative breast cancer (TNBC): A single-arm, prospective phase II study (MA-BC-II-026). () - Apr 23, 2025 - Abstract #ASCO2025ASCO_3921;
P2
Clinical Trial Registration Number: NCT06124001 The abstract will be released to the public on May 22, 2025 at 5:00 PM EDT Clinical Trial Registration Number: NCT05447702 The abstract will be released to the public on May 22, 2025 at 5:00 PM EDT
- AiRuiKa (camrelizumab) / HLB Bio Group
Camrelizumab plus nab-paclitaxel and cisplatin as first-line treatment for metastatic triple-negative breast cancer: A prospective, single-arm, open-label phase II trial. (Hall A - Posters and Exhibits; Poster Bd #: 80) - Apr 23, 2025 - Abstract #ASCO2025ASCO_3333;
P2
Clinical Trial Registration Number: NCT04537286. The abstract will be released to the public on May 22, 2025 at 5:00 PM EDT
- AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
Neoadjuvant camrelizumab plus apatinib and temozolomide for resectable stage II/III acral melanoma: The CAP 03-NEO trial. (E451) - Apr 23, 2025 - Abstract #ASCO2025ASCO_3060;
P2
The abstract will be released to the public on May 22, 2025 at 5:00 PM EDT Clinical Trial Registration Number: NCT05512481 The abstract will be released to the public on May 22, 2025 at 5:00 PM EDT
- Aqupla (nedaplatin) / Simcere, Fruzaqla (fruquintinib) / Takeda, AiRuiKa (camrelizumab) / HLB Bio Group
Fruquintinib in combination with camrelizumab and paclitaxel liposome and nedaplatin as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): A single-arm, phase II study. (Hall A - Posters and Exhibits; Poster Bd #: 332) - Apr 23, 2025 - Abstract #ASCO2025ASCO_2643;
P1/2
Clinical Trial Registration Number: NCT05512481 The abstract will be released to the public on May 22, 2025 at 5:00 PM EDT Clinical Trial Registration Number: NCT06010212 The abstract will be released to the public on May 22, 2025 at 5:00 PM EDT
- AiRuiKa (camrelizumab) / HLB Bio Group
Camrelizumab plus albumin-bound paclitaxel and S-1 as first-line treatment of HER-2 negative unresectable locally advanced or advanced gastric and gastroesophageal junction adenocarcinoma: A phase II clinical trial. (Hall A - Posters and Exhibits; Poster Bd #: 328) - Apr 23, 2025 - Abstract #ASCO2025ASCO_2640;
P4
Clinical Trial Registration Number: NCT06010212 The abstract will be released to the public on May 22, 2025 at 5:00 PM EDT Clinical Trial Registration Number: ChiCTR2300069672 The abstract will be released to the public on May 22, 2025 at 5:00 PM EDT
- AiRuiKa (camrelizumab) / HLB Bio Group
Safety and efficacy of camrelizumab combined with radiotherapy as neoadjuvant therapy for locally advanced esophageal squamous cell carcinoma: A prospective single-arm phase II clinical trial. (Hall A - Posters and Exhibits; Poster Bd #: 347) - Apr 23, 2025 - Abstract #ASCO2025ASCO_2603;
P1/2
Clinical Trial Registration Number: ChiCTR2300069672 The abstract will be released to the public on May 22, 2025 at 5:00 PM EDT Clinical Trial Registration Number: NCT05176002 The abstract will be released to the public on May 22, 2025 at 5:00 PM EDT
- Sulanda (surufatinib) / Hutchmed, AiRuiKa (camrelizumab) / HLB Bio Group
First-line treatment with surufatinib, camrelizumab, nab-paclitaxel, and S-1 in locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC): A phase Ib/II randomized study. (Hall A - Posters and Exhibits; Poster Bd #: 451) - Apr 23, 2025 - Abstract #ASCO2025ASCO_2474;
P1/2
Clinical Trial Registration Number: NCT05176002 The abstract will be released to the public on May 22, 2025 at 5:00 PM EDT Clinical Trial Registration Number: NCT05218889 The abstract will be released to the public on May 22, 2025 at 5:00 PM EDT
- AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
Camrelizumab plus apatinib in patients with advanced or refractory chordoma: A single-arm, open-label, phase 2 trial. (S100a) - Apr 23, 2025 - Abstract #ASCO2025ASCO_2025;
P2
Clinical Trial Registration Number: NCT05218889 The abstract will be released to the public on May 22, 2025 at 5:00 PM EDT Clinical Trial Registration Number: ChiCTR2100042938 The abstract will be released to the public on May 22, 2025 at 5:00 PM EDT
- AiRuiKa (camrelizumab) / HLB Bio Group
Camrelizumab combined with 2 cycles of chemotherapy as first-line treatment for advanced non-small cell lung cancer (NSCLC): A two-arm, single-center, phase 2 study. (Hall A - Posters and Exhibits; Poster Bd #: 28) - Apr 23, 2025 - Abstract #ASCO2025ASCO_1718;
P2
Clinical Trial Registration Number: ChiCTR2100042938 The abstract will be released to the public on May 22, 2025 at 5:00 PM EDT Clinical Trial Registration Number: ChiCTR2200065078 The abstract will be released to the public on May 22, 2025 at 5:00 PM EDT
- Erbitux (cetuximab) / Eli Lilly, AiRuiKa (camrelizumab) / HLB Bio Group
Camrelizumab combined with cetuximab and chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC): 1-year outcomes from the phase II trial. (Hall A - Posters and Exhibits; Poster Bd #: 438) - Apr 23, 2025 - Abstract #ASCO2025ASCO_1449;
P2
Clinical Trial Registration Number: ChiCTR2200065078 The abstract will be released to the public on May 22, 2025 at 5:00 PM EDT Clinical Trial Registration Number: NCT05673577 The abstract will be released to the public on May 22, 2025 at 5:00 PM EDT
- | AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
Journal, PD(L)-1 Biomarker, IO biomarker: Pathologically Complete Response to Camrelizumab and Apatinib in Advanced Cervical Cancer with PTEN, PIK3CA, MTOR, and ARID1A Mutations: A Case Report. (Pubmed Central) - Apr 21, 2025
Camrelizumab is affordable, at just 10% of the price of pembrolizumab, although it is similarly not covered by medical insurance for cervical cancer in China. The PTEN, PIK3CA, MTOR, and ARID1A gene mutations hold the potential to serve as predictive biomarkers for cervical cancer patients treated by PD-1 inhibitors.
- ||| Retrospective data, Review, Journal, Adverse events: Post-Treatment Adverse Events Ranking in Targeted Immunotherapy for Hepatocellular Carcinoma: A Network Meta-Analysis based on Risk Probability Assessment. (Pubmed Central) - Apr 19, 2025
The PTEN, PIK3CA, MTOR, and ARID1A gene mutations hold the potential to serve as predictive biomarkers for cervical cancer patients treated by PD-1 inhibitors. Cabozantinib, camrelizumab, and their combination therapy for HCC are associated with a higher incidence of common adverse reactions, whereas durvalumab, lenvatinib, and their combination therapy are less likely to cause common adverse effects.
- | Tevimbra (tislelizumab-jsgr) / BeiGene, Tyvyt (sintilimab) / Innovent Biologics, Eli Lilly, AiRuiKa (camrelizumab) / HLB Bio Group
Reimbursement, US reimbursement, Journal: Evaluation of changes in price, volume and expenditure of PD-1 drugs following the government reimbursement negotiation in China: a multiple-treatment period interrupted time series analysis. (Pubmed Central) - Apr 18, 2025
The GRN policy improved the accessibility and affordability of PD-1 drugs. Health insurance policy-makers need to consider the legitimate interests of PD-1 drug manufacturers while ensuring the sustainability of the basic health insurance fund.
- | carboplatin / Generic mfg., AiRuiKa (camrelizumab) / HLB Bio Group, albumin-bound paclitaxel / Generic mfg.
Journal: Synchronous triple squamous cell carcinomas of the stomach, skin and gingiva with liver, lung, spleen, kidney, bone and brain metastases: A case report. (Pubmed Central) - Apr 17, 2025
In the present case, a diagnosis of triple primary SCCs of the skin, stomach and gingiva with multiple organ metastases was made based on epidemiologic features and clinical presentation. The results of the present case report suggested that anti-programmed death 1 antibodies combined with platinum-based chemotherapy may be a treatment option for metastatic SCC.
- | New trial, Real-world evidence: Safety, Efficacy, and Survival Outcomes of Neoadjuvant/Induction Immunotherapy in Surgical and Radiotherapeutic Management of Non-Small Cell Lung Cancer (clinicaltrials.gov) - Apr 14, 2025
P=N/A, N=500, Recruiting, Sponsor: Peking University Cancer Hospital & Institute
- | hydroxychloroquine / Generic mfg., AiRuiKa (camrelizumab) / HLB Bio Group
Journal: Case Report: Subacute cutaneous lupus erythematosus induced by the anti-PD-1 antibody camrelizumab combined with chemotherapy. (Pubmed Central) - Apr 14, 2025
It is recommended to perform early antibody testing and skin biopsy for diagnosis and treatment. Unlike classic drug-related SCLE, patients may develop multiple autoimmune diseases, and caution should be taken when using immune checkpoint inhibitors for subsequent treatment.
- | carboplatin / Generic mfg., AiRuiKa (camrelizumab) / HLB Bio Group, albumin-bound paclitaxel / Generic mfg.
Journal: Evaluation of the efficacy and safety of neoadjuvant immunotherapy in locally advanced esophageal squamous cell carcinoma. (Pubmed Central) - Apr 14, 2025
The treatment warrants further investigation. Moreover, the TRG was found to be significantly associated with imaging assessment; these two approaches can be combined and employed to predict the efficacy of neoadjuvant immuno-chemotherapy.
- | AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
Journal, Metastases: A CT-Based Clinical-Radiomics Nomogram for Predicting the Overall Survival to TACE Combined with Camrelizumab and Apatinib in Patients with Advanced Hepatocellular Carcinoma. (Pubmed Central) - Apr 9, 2025
Moreover, the TRG was found to be significantly associated with imaging assessment; these two approaches can be combined and employed to predict the efficacy of neoadjuvant immuno-chemotherapy. A CT-based clinical-radiomics nomogram exhibits strong potential for predicting OS in advanced HCC patients undergoing TACE combined with camrelizumab and apatinib.
- | AiRuiKa (camrelizumab) / HLB Bio Group
Biomarker, Journal, PD(L)-1 Biomarker, IO biomarker: Plasma proteomic biomarkers predict therapeutic responses in advanced biliary tract cancer patients receiving Camrelizumab plus the GEMOX treatment. (Pubmed Central) - Apr 8, 2025
In addition, based on the obtained plasma and tissue samples, two nomogram models were constructed for predicting the prognosis of BTC by genome combined with proteomics. Collectively meaningful proteomic biomarkers are beneficial to evaluate the efficacy of immunotherapy, and these discovered biomarkers may be included in the scope of treatments' evaluation and improvement in future study.
- | AiRuiKa (camrelizumab) / HLB Bio Group
Journal: A case of camrelizumab-induced anaphylaxis and successful rechallenge: a case report and literature review. (Pubmed Central) - Apr 7, 2025
He underwent multiple cycles of therapy, tolerating camrelizumab, nab-paclitaxel, and nedaplatin (200 mg of camrelizumab every 3 weeks) without adverse reactions in the first four cycles...The camrelizumab infusion was immediately halted, and the patient was treated with intravenous dexamethasone (10 mg) combined with intramuscular diphenhydramine, calcium gluconate, and 500 ml of normal saline; his blood pressure gradually increased to 110/80 mmHg within 10 minutes, and pruritic erythematous macules appeared on his skin, particularly on the upper limbs...The patient did not report significant discomfort. Although acute allergic reactions are relatively rare among immune-related adverse events, due to the widespread clinical application of camrelizumab, its potential for allergic reactions should be given high priority.
- || Herceptin (trastuzumab) / Roche, AiRuiKa (camrelizumab) / HLB Bio Group
P2 data, Journal: Neoadjuvant camrelizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastroesophageal junction adenocarcinoma: a single-arm, phase 2 trial. (Pubmed Central) - Apr 4, 2025
Although acute allergic reactions are relatively rare among immune-related adverse events, due to the widespread clinical application of camrelizumab, its potential for allergic reactions should be given high priority. Neoadjuvant camrelizumab plus trastuzumab and chemotherapy demonstrated favorable response and tolerable safety in HER2-positive G/GEJ adenocarcinoma.
- | recaticimab (SHR-1209) / Jiangsu Hengrui Pharma, AiRuiKa (camrelizumab) / HLB Bio Group
New trial: Prospective, exploratory clinical study of Camrelizumab combined with Recaticimab for first-line maintenance in advanced NSCLC (EUDRACT) - Apr 2, 2025
P=N/A, N=37, Not yet recruiting, Sponsor: First Affiliated Hospital of Zhengzhou University; First Affiliated Hospital of Zhengzhou University
- | AiRuiKa (camrelizumab) / HLB Bio Group
New trial: Mechanism and clinical study of neoadjuvant immunotherapy combined with chemotherapy in the treatment of pMMR/MSS type locally advanced colon cancer (EUDRACT) - Apr 2, 2025
P=N/A, N=68, Not yet recruiting, Sponsor: The Affiliated Hospital of Guizhou Medical University; The Affiliated Hospital of Guizhou Medical University
- | AiRuiKa (camrelizumab) / HLB Bio Group
New trial: Camrelizumab combined with chemotherapy and local consolidation therapy as first-line treatment in oligo-metastasis non-small cell lung caner with PD-L1? 50% : a single-arm phase 2 clinical study(CONTROL) (EUDRACT) - Apr 2, 2025
P=N/A, N=35, Not yet recruiting, Sponsor: The Affiliated Panyu Central Hospital, Guangzhou Medical University; The Affiliated Panyu Central Hospital, Guangzhou Medical University
- | AiTan (rivoceranib) / HLB Bio Group, Halaven (eribulin mesylate) / Eisai, AiRuiKa (camrelizumab) / HLB Bio Group
New trial: Clinical Study on the Efficacy of Immunotherapy Combined with Targeted Therapy and Chemotherapy Versus Investigator's Choice Chemotherapy in Advanced Triple-Negative Breast Cancer (EUDRACT) - Apr 2, 2025
P=N/A, N=246, Not yet recruiting, Sponsor: Sun Yat-sen Memorial Hospital Sun Yat-sen University; Sun Yat-sen Memorial Hospital Sun Yat-sen University
- | AiRuiKa (camrelizumab) / HLB Bio Group
New trial: Clinical evaluation of 125 Iodine seed loaded stents combined with chemotherapy and immunotherapy for locally advanced esophageal carcinoma (EUDRACT) - Apr 2, 2025
P=N/A, N=19, Recruiting, Sponsor: Affiliated Zhongda Hospital of Southeast University; Affiliated Zhongda Hospital of Southeast University
- | AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
New P3 trial: A multicenter, prospective, cohort study exploring the efficacy and safety of portal vein ligation combined with hepatic arterial infusion chemotherapy and systemic therapy versus ALPPS in the conversion treatment of hepatocellular carcinoma with inadequate future-liver-remnant (EUDRACT) - Apr 2, 2025
P3, N=110, Not yet recruiting, Sponsor: The First Affiliated Hospital of Guangxi Medical University; The First Affiliated Hospital of Guangxi Medical University
- | AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
New P2 trial: Hepatic arterial infusion chemotherapy (HAIC) combined with carrilizumab and apatinib mesylate conversion therapy for unresectable hepatocellular carcinoma with portal vein cancer thrombus is an open, single-arm, multicenter, prospective clinical study (EUDRACT) - Apr 2, 2025
P2, N=13, Not yet recruiting, Sponsor: Drum Tower Hospital; Drum Tower Hospital